Trends in acute coronary heart disease morbidity and mortality in the adult population of the Russian Federation in 2012-2017

1 million 824 thousand people died in the Russian Federation in 2017, including 457 thousand from ischemic heart disease (IHD). IHD caused more than a quarter of deaths in Russia. Goal. The article analyzes the impact of implementation of clinical guidelines in cardiology in medical practice in the United States and the Russian Federation on the dynamics of mortality from ischemic heart disease and its outcomes in different age groups. Results. The results showed that the implementation of clinical guidelines (CG) increased the rate of mortality reduction from coronary heart diseases in Russia and the United States, which may indicate a positive impact CG on the quality of medical care. Conclusions. A higher level of mortality from coronary heart disease in Russia compared to the United States may be due to less commitment of doctors to the principles of therapy and diagnosis of various forms of coronary heart disease, set out in clinical guidelines.

Download Full-text

The analysis of high cardiovascular morbidity and mortality in the adult population as a medical and social problem and the search for ways to solve it

Уральский медицинский журнал ◽

10.52420/2071-5943-2021-20-1-58-64 ◽

2021 ◽

Vol 20 (1) ◽

pp. 58-64

Author(s):

V. P. Kosolapov ◽

M. V. Yarmonova

Keyword(s):

Mortality Rate ◽

Russian Federation ◽

Social Problem ◽

Adult Population ◽

Cardiovascular Morbidity ◽

Morbidity And Mortality ◽

High Morbidity ◽

Demographic Situation ◽

Voronezh Region ◽

The Russian Federation

Introduction. The article is devoted to the analysis of the state of cardiovascular morbidity (CVD), mortality of the population and the demographic situation, as well as determining the prevalence of CVD as a medical and social problem at the federal and regional levels. The analysis of the implementation of the policy of providing medical care to patients with CVD, modern scientific publications on the indicated problem, and the search for ways to solve the medical and social problem of high morbidity and mortality from CVD are carried out.Materials and methods. The data of official statistical information on the morbidity and mortality of the adult population of the Russian Federation and the Voronezh region for 2010–2019 were used, the works of modern domestic and foreign scientists dealing with the solution of this problem were studied.Results. It has been established that high CVD and mortality are an acute medical and social problem. Mortality from CVD in Russia in 2019 amount to 46.8% of the total number of deaths. The mortality rate from CVD in Russia exceeds that in the developed countries of the European Union. Despite the presence of positive trends in the fight against this disease, the mortality rate from CVD in the Voronezh region is higher than the average for the Russian Federation (601.8 and 573.2 per 100 thousand population, respectively). The deterioration of the demographic situation, the presence of active targeted projects in this area are the basis for conducting scientific research to find ways to duce CVD and mortality in the adult population.Conclusion. The high morbidity and mortality from CVD requires a search for new ways to solve the problem, since the existing approaches to its solution are not holistic and universal. It is urgent to develop an integrated approach that takes into account the medical and social characteristics of the adult population of the region.

Download Full-text

Features of the Formation of Disability due to Coronary Heart Disease in People of Retirement Age in the Russian Federation in the Period 2006–2017

Advances in Gerontology ◽

10.1134/s2079057019030159 ◽

2019 ◽

Vol 9 (3) ◽

pp. 355-360

Author(s):

S. A. Chandirli ◽

S. N. Puzin ◽

O. T. Bogova ◽

V. N. Potapov

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Russian Federation ◽

Retirement Age ◽

The Russian Federation

Download Full-text

WHY CARDIOVASCULAR MORTALITY IN MOSCOW IS LOWER THAN IN OTHER REGIONS OF THE RUSSIAN FEDERATION?

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2015-2-4-12 ◽

2015 ◽

Vol 14 (2) ◽

pp. 4-12

Author(s):

N. V. Pogosova ◽

R. G. Oganov ◽

S. V. Suvorov

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Medical Care ◽

Russian Federation ◽

Cardiovascular Mortality ◽

High Technology ◽

Economic Level ◽

The Russian Federation ◽

In The Beginning ◽

Cvd Mortality

Since 2003 there is a decline of cardiovascular (CVD) mortality of the RF, that established in 2006 in women and in men. From 2003 to 2013 y. total coefficient of cardiovascular mortality (number of died per 100 thousand of population) decreased by 25% (698,1 vs. 927,5), although still it is higher than in the beginning of the nineties (621,0 per 100 thous. of population in 1991 y.). The significant differences in RG regions are noted by the values of morbidity and mortality from CVD. For the period 2006-2013 y. the standardized value of mortality from coronary heart disease (CHD) in Moscow decreased by 35,7% that is 1,5 more than in RF and 1,3 more higher than in St-Petersburg, and 2,6 times more than in Moscow region. In 2012 the value of the suspected life duration (SLD) of Moscow citizens was 76,0 y. (mean in Russia — 70,0 y), and just 4 years is the gap between then and EU citizens. In 2013 SLD in Moscow reached 72,3 y. Significantly lower values of mortality from CVD and higher values of SLD can be explained by higher socio-economic level, higher psychological endurance and better availability of psychological (psychotherapeutic) help, higher level of fish, fruits and berries consumption, better availability of outpatient and high technology medical care for Moscow citizens.

Download Full-text

Choosing an antianginal therapy strategy in patients with stable coronary artery disease in real clinical practice: the advantages of trimetazidine

Medical Council ◽

10.21518/2079-701x-2021-12-25-32 ◽

2021 ◽

pp. 25-32

Author(s):

E. V. Borisova ◽

O. D. Ostroumova ◽

A. P. Pereverzev ◽

E. E. Pavleeva

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Russian Federation ◽

Stable Coronary Artery Disease ◽

Cardiovascular Complications ◽

Ministry Of Health ◽

Conduction Disorders ◽

Therapy Strategy ◽

Stable Coronary Heart Disease ◽

The Russian Federation

Cardiovascular diseases (CVD) are the leading cause of death among adults worldwide, including in the Russian Federation. At the same time, the leading position in the structure of causes of death from CVD is occupied by coronary heart disease (CHD) (16% of the total number of deaths in the world per year). The new clinical guidelines of the Ministry of Health of the Russian Federation for the management of patients with stable coronary heart disease in 2020 identify two main goals of conservative therapy – the elimination of symptoms of the disease and the prevention of cardiovascular complications (CVD). In this connection, when choosing antianginal therapy in patients with stable angina, it is necessary to consider the possibility of using combinations of both first-line and second-line drugs in order to really improve the effectiveness of treatment and achieve the goals set. It is advisable and justified to use more widely 2-line drugs, in particular trimetazidine, at any stage of therapy to enhance the antianginal effectiveness of b-blockers, calcium antagonists and prolonged-acting nitrates, especially in patients with hemodynamic features (arterial hypotension, rhythm and conduction disorders), which is demonstrated in the given clinical example. The effective addition of tremetazidine to the arsenal of traditional antianginal drugs is legislated in practice and is reflected in the new clinical recommendations of the Ministry of Health of the Russian Federation in 2020. The accumulated experience of using trimetazidine allows a pathogenetically sound approach to the treatment of stable CHD, restoring the balance between the need and delivery of oxygen to the heart muscle, and the safety profile expands the possibilities of use in patients with comorbid pathology.

Download Full-text